Carmell Therapeutics will merge with a New York-based special purpose acquisition company in a deal worth $328 million. Carmell, a 14-year-old biotech firm based on the South Side, had filed in September a registration statement with the U.S. Securities and Exchange Commission announcing its intention to go public. The company will go public in the deal with Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA), and the combined company will be known as Carmell Therapeutics Corp. and trade on the Nasdaq Capital Market with the ticker symbol CTCX.